Hemodynamic and Renal Effects of ProANF 31–67 in Hypertensive Rats

Abstract

Abstract

It has been demonstrated previously that the atrial natriuretic factor prohormone fragment 31–67 (ProANF_31–67) circulates in animals and possesses natriuretic and vasodilating actions. Although the plasma levels of the peptide are reportedly elevated in patients with high blood pressure, its role and actions in hypertension are unknown. In the present study, synthetic human ProANF_31–67 was infused intravenously at doses of 0, 10, 30, and 100 ng/kg/min into respective groups of anesthetized normotensive and spontaneously hypertensive rats. Mean arterial pressure (MAP), urine flow rate (UV), and sodium excretion (U_NaV) were measured during two consecutive 30-min periods. In both strains of rats, reductions in MAP with ProANF_31–67 were similar in magnitude and dose-related. Sodium excretion responses to the peptide infusions also were remarkably similar in both normotensive and hypertensive rats, and the responses demonstrated 3- to 5-fold (P < 0.05) increments compared to control at the doses of 10 and 30 ng/kg/min. However, in the two strains of rats, attenuation of natriuresis occurred with the highest infusion dose of 100 ng/kg/min and was probably related to the large decreases in MAP of 17–23 mmHg at this dose of the peptide. The present results indicate the ProANF_31–67 has important hemodynamic and renal effects in hypertension and may represent one compensatory mechanism involved in this disease.